Maze Therapeutics, Inc. Common Stock MAZE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $198.77M+5.0% | $189.25M-40.3% | $316.77M+19.7% | $264.54M-10.1% | $294.37M+49.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $379.78M+8.6% | $349.72M-10.6% | $391.3M— | —— | —— | ||
| $4.68M-7.2% | $5.04M-8.9% | $5.54M— | —— | —— | ||
| $419.71M+5.7% | $397.13M-5.9% | $422.06M— | —— | —— | ||
| $12.39M+14.9% | $10.78M-1.3% | $10.93M+59.8% | $6.84M+92.1% | $3.56M+290% | ||
| —— | —— | —— | —— | —— | ||
| $21.24M-5.9% | $22.56M+2.0% | $22.11M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $78.01M+85.0% | $42.16M-1.1% | $42.62M— | —— | —— | ||
| $50K+2.0% | $49K+2.1% | $48K— | —— | —— | ||
| -$513.76M-4.9% | -$489.55M-7.6% | -$454.98M— | —— | —— | ||
| $341.7M-3.7% | $354.97M-6.4% | $379.44M— | —— | —— | ||
| $419.71M+5.7% | $397.13M-5.9% | $422.06M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Maze Therapeutics, Inc. Common Stock's total assets?
- Maze Therapeutics, Inc. Common Stock (MAZE) holds $419.7M in total assets, up 26.1% year over year.
- How much debt does Maze Therapeutics, Inc. Common Stock have?
- Maze Therapeutics, Inc. Common Stock carries $61.2M in total debt against $341.7M of shareholders' equity, a debt-to-equity ratio of 0.18.
- How much cash does Maze Therapeutics, Inc. Common Stock have?
- Maze Therapeutics, Inc. Common Stock holds $198.8M in cash and equivalents.
- Can Maze Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 17.88 — current assets exceed current liabilities.
- Where does Maze Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
